摘要
声门型喉癌占喉癌发病的70%,淋巴结转移少见。早期声门型喉癌常常引起声音嘶哑,就诊过程中,易于早期发现,在所有喉癌中预后最好。近10年来美国国家综合癌症网络(NCCN)指南中关于早期声门型喉癌的诊治经历20余次的更新,已逐步形成经口内镜下CO_(2)激光手术或单纯放疗为主的治疗模式。喉功能保留和嗓音质量是衡量治疗成功与否的关键因素,目前开放手术的应用越来越少,而首选CO_(2)激光手术还是单纯放射治疗方案的问题一直是悬而未决的。本文将分别介绍早期声门型喉癌的治疗进展及个性化治疗选择的关键要点,并总结影响肿瘤复发的预后因素及预测复发的生物学标志物,以期为指导早期声门型喉癌患者的治疗及随访提供临床参考。
Glottic cancer accounts for 70%of the laryngeal cancer,and lymph node metastasis is rare.Early glottic cancer often causes hoarseness,which is easy to detect early in the process of treatment and has the best prognosis of all laryngeal cancers.In the past 10 years,the guidelines of the National Comprehensive Cancer Network(NCCN)in the United States on the diagnosis and treatment of early glottic cancer have been updated more than 20 times,and the treatment mode of transoral CO_(2) laser microsurgery or radiotherapy alone has gradually formed.Laryngeal preservation and voice quality are key factors in measuring the success of treatment.At present,there are fewer and fewer open surgeries,and the question of whether transoral CO_(2) laser microsurgery or radiotherapy alone is the preferred treatment option has been unresolved.This article introduces the progress of early glottic cancer treatment and the key points of personalized treatment selection,and summarizes the prognostic factors affecting tumor recurrence and the biomarkers for predicting recurrence,in order to provide clinical reference for guiding the treatment and follow-up of early glottic cancer patients.
作者
陈曦
陆兆屹
CHEN Xi;LU Zhaoyi(Department of Otorhinolaryngology,the First Affiliated Hospital,Nanjing Medical University,Jiangsu Province Hospital,Nanjing 210029,China)
出处
《中国耳鼻咽喉颅底外科杂志》
CAS
CSCD
2024年第3期1-8,共8页
Chinese Journal of Otorhinolaryngology-skull Base Surgery
基金
江苏省卫生健康委面上项目(H2019001)
江苏省自然科学基金(BK20230739)。
关键词
早期声门型喉癌
治疗
复发
个性化
Early glottic cancer
Treatment
Recurrence
Individualization
